The purpose of the report is to illustrate the state of the market of Carcinoembryonic Antigen, to present actual information about the volumes of production, exports, imports, consumption and the state of the market, the changes that took place in 2017, and also, to build a forecast for the growth of the industry in the medium term until 2026.
Browse here for full report with Toc: https://www.credenceresearch.com/report/carcinoembryonic-antigen-cea-market
According to Quest Diagnostics, CEA is an oncofetal glycoprotein present in the gastrointestinal tract and body fluids of the embryo and fetus. This antigen is also present in certain adult gastrointestinal cells, including the mucosal cells of the colorectum, and small amounts are present in blood. Market experts suggest that key growth drivers assisting the growth of CEA market comprises high prevalence of cancer, mounting global geriatric population base, high demand for minimally invasive diagnostic procedures in cancer and increasing application of CEA for diagnosis at several stages of cancer. In addition, a few factors that assist the overall market growth are growing healthcare expenditure which is boosting the need for efficient diagnostic procedure for cancer and influencing the usage of combination biomarkers.
The market is dominated by several players, depending on their major competencies. The key players in this market are Quest Diagnostics, F. Hoffman LA Roche, Abbott Laboratories, GenWay Biotech Inc., Correlogic Systems, Inc., and Others.
Why was the report written?
This report is the result of an extensive survey drawn from Credence Research’s exclusive panel of leading global market industry executives; it provides data and analysis on buyer investment, acquisition, and developments within the global market research. It includes key topics such as global Carcinoembryonic Antigen buyer expenditure and procurement behaviors and strategies and recognizes the threats and possibilities within the industry, economic outlook trends, and business confidence within global industry executives. Most secondary research reports are based on general industry drivers and do not understand the industry executives’ attitude and changing behaviors, creating a gap in presenting the business outlook of the industry; in an effort to bridge this gap, Credence Research created this primary research-based report by gathering the opinions of multiple stakeholders in the value chain of the global industry.
What is the current market landscape and what is changing?
Executives from the global industry anticipate an increase in levels of consolidation, with 55% of respondents projecting an increase in merger and acquisition (M&A) activities in 2017.
The report on the market of Carcinoembryonic Antigen contains:
Analysis and forecast of Carcinoembryonic Antigen market dynamics;
Analysis of domestic production, market shares of the main market players;
Analysis of exports and imports;
Analysis of factors, leading the development of the Carcinoembryonic Antigen market;
Assessment and forecast of Carcinoembryonic Antigen market development;
Financial and business profiles of the leading companies in the Carcinoembryonic Antigen industry.
Also you can request us for sample in PDF with depth details and graph: https://www.credenceresearch.com/sample-request/58091
– Up to date working Carcinoembryonic Antigen data by major regions in the world, the forecast of planned capacity additions by 2026
– The annual breakdown of capital expenditure spending on proposed Carcinoembryonic Antigen for the period 2018 to 2026
– Planned Carcinoembryonic Antigen additions and capital expenditure spending by key countries and companies across the world
– Planned capital expenditure spending on new Carcinoembryonic Antigen projects by region, key countries, and companies
– Details of major planned Carcinoembryonic Antigen projects in the world up to 2026
Credence Research is a worldwide market research and counseling firm that serves driving organizations, governments, non-legislative associations, and not-for-benefits. We offer our customers some assistance with making enduring enhancements to their execution and understand their most imperative objectives. Over almost a century, we’ve manufactured a firm extraordinarily prepared to this task.
Credence Research Inc.
105 N 1st ST #429
Toll Free (US/CANADA): +1-800-361-8290